TBX5

Across TCGA pan-cancer cohorts, TBX5 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TBX5 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher TBX5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBX5 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

DLBC, CESC, and STAD are the cancer types where TBX5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
CESC	DFS	Median	III,IV	0.091	0.728	<.001	24	view →
STAD	DFS	Median	III,IV	1.000	0.334	.024	12	view →
GBM	OS	Median	All	0.109	0.415	.032	6	view →
BLCA	DFS	Median	All	0.116	0.354	.025	4	view →
UCEC	DFS	Median	All	0.899	0.616	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TBX5–DLBC (OS)

Open the DLBC breakdown →